<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2023-112-119</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3288</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Диастолическая дисфункция левого и правого желудочков у пациентов с болезнью депонирования кристаллов пирофосфатов кальция и остеоартритом.</article-title><trans-title-group xml:lang="en"><trans-title>Diastolic dysfunction of the left and right ventricles in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а </p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5394-7869</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Желябина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zheliabina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Желябина Ольга Владимировна</p><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а  </p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A </p></bio><email xlink:type="simple">olga-sheliabina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1003-2087</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кириллова</surname><given-names>И. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirillova</surname><given-names>I. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а </p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3052-7466</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корсакова</surname><given-names>Ю. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Korsakova</surname><given-names>Yu. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а </p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4383-9872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черёмушкина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Cheremushkina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Российская Федерация, Москва, Каширское шоссе, 34а </p></bio><bio xml:lang="en"><p>115522, Russian Federation, Moscow, Kashirskoye Highway, 34A </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>06</day><month>03</month><year>2023</year></pub-date><volume>61</volume><issue>1</issue><fpage>112</fpage><lpage>119</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеев М.С., Желябина О.В., Кириллова И.Г., Корсакова Ю.О., Черёмушкина Е.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Елисеев М.С., Желябина О.В., Кириллова И.Г., Корсакова Ю.О., Черёмушкина Е.В.</copyright-holder><copyright-holder xml:lang="en">Eliseev M.S., Zheliabina O.V., Kirillova I.G., Korsakova Y.O., Cheremushkina E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3288">https://rsp.mediar-press.net/rsp/article/view/3288</self-uri><abstract><p>Частота и факторы риска (ФР) развития диастолической дисфункции (ДД) у пациентов с болезнью депонирования кристаллов пирофосфатов кальция (БДПК) и остеоартритом (ОА) не изучены.Цель исследования – определить частоту и выявить факторы риска развития диастолической функции левого (ЛЖ) и правого (ПЖ) желудочков у пациентов с болезнью депонирования кристаллов пирофосфатов кальция и остеоартритом.Материал и методы. Включено по 26 пациентов (возраст – 18 65 лет) с БДПК и с ОА коленных суставов, сопоставимых по возрасту и полу, без сердечно-сосудистых заболеваний (ССЗ). Оценивались традиционные ФР ССЗ, проводилась эхокардиография.Результаты. Частота ДД у пациентов с БДПК и ОА была довольно высокой и почти не различалась в обеих группах. ДД выявлена у 19 пациентов, в том числе у 11 (42%) – при БДПК и у 8 (31%) – при ОА (р=0,39). Выявлялась ДД ЛЖ 1-го типа у 10 (39%) пациентов с БДПК и у 8 (31%) – с ОА (р=0,11); ДД ПЖ 1-го типа – у 8 (31%) и 7 (27%) пациентов соответственно (р=0,17). ДД ЛЖ и ДД ПЖ 1-го типа выявлены у 7 (27%) пациентов как с БДПК, так и с ОА. ДД 2-го и 3-го типов в обеих группах выявлена не была. Не было выявлено различий в обеих группах по ФР ССЗ, кроме уровня C-реактивного белка (СРБ), который был выше при БДПК (p=0,03).В группе БДПК средние значения отношения максимальной скорости раннего диастолического наполнения митрального потока к ранней диастолической скорости движения фиброзного кольца митрального клапана (Е/Е′) ЛЖ (р=0,02), время замедления раннего диастолического наполнения (ДТ) ЛЖ (р=0,03), индекс массы миокарда (ИММ) ЛЖ (р=0,04) были статистически значимо выше, чем при ОА. Напротив, у пациентов с ОА конечный диастолический объем ЛЖ (р=0,004) и ДТ ПЖ (р=0,02) были выше. При БДПК выявлены прямые корреляционные связи между показателями ДД и следующими факторами: пиковой скоростью раннего диастолического наполнения (Е) ЛЖ и сывороточным уровнем паратгормона (ПТГ) (r=0,7; р&lt;0,005); толщиной задней стенки ЛЖ и сывороточным уровнем ПТГ (r=0,6; р&lt;0,005); скоростью движения фиброзного кольца в раннюю диастолу (Е′) ЛЖ и сывороточным уровнем ПТГ (r=0,7; р&lt;0,005). Обратная корреляция была выявлена между толщиной межжелудочковой перегородки и сывороточной концентрацией ПТГ (r=–0,5; р&lt;0,005), сывороточным уровнем ПТГ с ИММ ЛЖ (r=–0,5; р&lt;0,005), содержанием витамина D и ДТ ПЖ (r=–0,6; р&lt;0,005). У пациентов с ОА положительные корреляционные связи отмечались между уровнем витамина D и Е/Е′ ЛЖ (r=0,6; р&lt;0,005). Площадь правого желудочка в диастолу обратно коррелировала с концентрацией СРБ (r=–0,6; р&lt;0,005) и сывороточным уровнем мочевой кислоты (МК) (r=–0,7; р&lt;0,005).Вывод. Выявлена высокая распространенность ДД ЛЖ и ПЖ у пациентов с БДПК и ОА. Наличие ДД при БДПК ассоциировалось с более низким уровнем витамина D, а при ОА – с более высоким уровнем МК и более низким уровнем ПТГ.</p></abstract><trans-abstract xml:lang="en"><p>The frequency and risk factors for the development of diastolic function in patients with calcium pyrophosphate crystal deposition disease (CPPD) and osteoarthritis (OA) have not been studied.The aim – to determine the frequency and to identify risk factors (RF) for the development of diastolic dysfunction (DD) of the left (LV) and right (RV) ventricles in patients with calcium pyrophosphate crystal deposition disease and osteoarthritis.Material and methods. 26 patients (18–65 years) each were included with CPРD and with knee OA, matched in age and gender, without cardiovascular disease (CVD), type 2 diabetes mellitus, rheumatic diseases. Traditional risk factors of CVD were assessed, echocardiography was performed.Results. The frequency of DD in patients with CPРD and OA was quite high and almost did not differ in both groups: it was detected in 19 patients, of which 11 (42%) with CPРD and 8 (31%) with OA (p=0.39). Type 1 LV DD was detected in 10 (39%) patients with CPРD and in 8 (31%) with OA (p=0.11); type 1 RV DD – in 8 (31%) patients with CPРD and in 7 (27%) patients with OA (p=0.17); type 1 LV DD and RV DD – in 7 (27%) patients with both CPРD and with OA. DD types 2 and 3 were not detected in both groups. There were no differences in both groups in CV risk factors, except for the level of C-reactive protein (CRP) – it was higher in CPРD (p=0.03). In the CPРD group, mean values of LV E/E′ (p=0.02), LV DT (p=0.03), LV MI (p=0.04) were significantly higher than in patients with OA. On the contrary, in patients with OA, the following indicators: EDV (p=0.004), TVC (p=0.02) were higher.There were direct correlations between diastolic function indices and the following factors in CPРD: LVL, PWLV and PTH level (r=0.7; p&lt;0.005), LV E′ and PTH level (r=0.7; p&lt;0.005); inverse correlations – the level of PTH and IS (r=–0.5; p&lt;0.005), LV MI (r=–0.5; p&lt;0.005), the level of vitamin D and VD DT (r=–0.6; p&lt;0.005). Direct correlations in OA: the level of CRP and PVAdiast (r=0.6; p&lt;0.005), and the level of sUA (r=0.7; p&lt;0.005), the level of vitamin D and E/E′ LV (r=0.6; p&lt;0.005).Conclusion. A high prevalence of LV and RV DD was found in patients with CPРD and OA. The presence of DD in CPРD was associated with lower vitamin D levels, and in OA with a higher level of sUA and a lower level of PTH.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>диастолическая дисфункция</kwd><kwd>болезнь депонирования кристаллов пирофосфата кальция</kwd><kwd>остеоартрит</kwd><kwd>паратгормон</kwd><kwd>витамин D</kwd><kwd>мочевая кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>diastolic dysfunction</kwd><kwd>calcium pyrophosphate crystal deposition disease</kwd><kwd>osteoarthritis</kwd><kwd>parathyroid hormone</kwd><kwd>vitamin D</kwd><kwd>uric acid</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена в рамках научного исследования «Оптимизация методов симптоматической противовоспалительной терапии у пациентов с микрокристаллическими артритами (подагра, болезнь депонирования кристаллов пирофосфата кальция)» (№ 2020-397-007).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Фомин ИВ. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. doi: 15829/1560-4071-2016-8-7-13</mixed-citation><mixed-citation xml:lang="en">Fomin IV. Chronic heart failure in Russian Federation: What do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13 (In Russ.). doi: 15829/1560-4071-2016-8-7-13</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Новикова АМ, Желябина ОВ, Герасимова ЕВ, Ильиных ЕВ, Попкова ТВ, и др. Оценка сердечно-сосудистого риска у пациентов с микрокристаллическими артритами и ревматоидным артритом с помощью шкал ATP III и Reynolds Risk Score. Научно-практическая ревматология. 2020;58(5):512-519. doi: 10.47360/1995-4484-2020-512-519</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Novikova AM, Zhelyabina OV, Gerasimova EV, Ilyinykh EV, Popkova TV, et al. Assessment of cardiovascular risk in patients with crystal-induced arthritides and rheumatoid arthritis by the ATP III and Reynolds Risk Score. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(5):512-519 (In Russ.). doi: 10.47360/1995-4484-2020-512-519</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Turkiewicz A, Kiadaliri AA, Englund M. Cause-specific mortality in osteoarthritis of peripheral joints. Osteoarthritis Cartilage. 2019;27(6):848-854. doi: 10.1016/j.joca.2019.02.793</mixed-citation><mixed-citation xml:lang="en">Turkiewicz A, Kiadaliri AA, Englund M. Cause-specific mortality in osteoarthritis of peripheral joints. Osteoarthritis Cartilage. 2019;27(6):848-854. doi: 10.1016/j.joca.2019.02.793</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Черёмушкина ЕВ, Желябина ОВ, Чикина МН, Капитонова АА, Новикова АА, и др. Влияние терапии колхицином, метотрексатом и гидроксихлорохином на сердечнососудистые исходы у пациентов с болезнью депонирования кристаллов пирофосфата кальция. Современная ревматология. 2021;15(6):76-83. doi: 10.14412/1996-7012-2021-6-76-83</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Cheremushkina EV, Zhelyabina OV, Chikina MN, Kapitonova AA, Novikova AA, et al. Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease. Modern Rheumatology Journal. 2021; 15(6):76-83 (In Russ). doi: 10.14412/1996-7012-2021-6-76-83</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Фомин ИВ, Беленков ЮН, Мареев ВЮ , Агеев ФТ, Бадин ЮВ, Галявич АС, и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Журнал сердечная недостаточность. 2006;7(3):112-115.</mixed-citation><mixed-citation xml:lang="en">Fomin IV, Belenkov YuN, Mareev VYu, Ageev FT, Badin YuV, Galyavich AS, et al. Prevalence of chronic heart failure in the European part of the Russian Federation: Data of the EPOCH-CHF. Zhurnal serdechnaya nedostatochnost. 2006;7(3):112-115 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507-515. doi: 10.1038/nrcardio.2014.83</mixed-citation><mixed-citation xml:lang="en">Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507-515. doi: 10.1038/nrcardio.2014.83</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch. 2014;466(6):1037-1053. doi: 10.1007/s00424-014-1480-8</mixed-citation><mixed-citation xml:lang="en">Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. Pflugers Arch. 2014;466(6):1037-1053. doi: 10.1007/s00424-014-1480-8</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: Pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993;22:318-325.</mixed-citation><mixed-citation xml:lang="en">Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: Pathophysiology and therapeutic implications. J Am Coll Cardiol. 1993;22:318-325.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373-394.</mixed-citation><mixed-citation xml:lang="en">Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373-394.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tausche AK, Reuss-Borst M. Kristallarthritiden [Crystal arthropathies]. Dtsch Med Wochenschr. 2019;144(15):1055-1060. doi: 10.1055/a-0857-0916</mixed-citation><mixed-citation xml:lang="en">Tausche AK, Reuss-Borst M. Kristallarthritiden [Crystal arthropathies]. Dtsch Med Wochenschr. 2019;144(15):1055-1060. doi: 10.1055/a-0857-0916</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mobasheri A, Matta C, Zákány R, Musumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas. 2015;80(3):237-244. doi: 10.1016/j.maturitas.2014.12.003</mixed-citation><mixed-citation xml:lang="en">Mobasheri A, Matta C, Zákány R, Musumeci G. Chondrosenescence: definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas. 2015;80(3):237-244. doi: 10.1016/j.maturitas.2014.12.003</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. doi: 10.1016/j.jacc.2013.02.092</mixed-citation><mixed-citation xml:lang="en">Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. doi: 10.1016/j.jacc.2013.02.092</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-570. doi: 10.1136/ard.2010.139105</mixed-citation><mixed-citation xml:lang="en">Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis. Ann Rheum Dis. 2011;70(4):563-570. doi: 10.1136/ard.2010.139105</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ (ред.). Ревматология: клинические рекомендации. М.:ГЭОТАР-Медиа;2011. [Nasonov EL (ed.). Rheumatology: Clinical recommendations. Moscow: GEOTAR-Media;2011 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Nasonov EL (ed.). Rheumatology: Clinical recommendations. Moscow: GEOTAR-Media;2011 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010;69(3):483-489. doi: 10.1136/ard.2009.113100</mixed-citation><mixed-citation xml:lang="en">Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010;69(3):483-489. doi: 10.1136/ard.2009.113100</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lafitte S. Do we need new echocardiographic prognosticators for the management of heart failure patients? J Am Coll Cardiol. 2009;54(7):625-627. doi: 10.1016/j.jacc.2009.04.058</mixed-citation><mixed-citation xml:lang="en">Lafitte S. Do we need new echocardiographic prognosticators for the management of heart failure patients? J Am Coll Cardiol. 2009;54(7):625-627. doi: 10.1016/j.jacc.2009.04.058</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2):79-108. doi: 10.1016/j.euje.2005.12.014</mixed-citation><mixed-citation xml:lang="en">Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.; American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2):79-108. doi: 10.1016/j.euje.2005.12.014</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-618. doi: 10.1161/01.cir.55.4.613</mixed-citation><mixed-citation xml:lang="en">Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-618. doi: 10.1161/01.cir.55.4.613</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi: 10.15829/1560-4071-2020-4083</mixed-citation><mixed-citation xml:lang="en">Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083 (In Russ.). doi: 10.15829/1560-4071-2020-4083</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898-904. doi: 10.1001/jama.290.7.898</mixed-citation><mixed-citation xml:lang="en">Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898-904. doi: 10.1001/jama.290.7.898</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005</mixed-citation><mixed-citation xml:lang="en">Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935-2959. doi: 10.1016/j.jacc.2013.11.005</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, et al. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020;27(Suppl 2):46-51. doi: 10.1177/2047487320961980</mixed-citation><mixed-citation xml:lang="en">Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, et al. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020;27(Suppl 2):46-51. doi: 10.1177/2047487320961980</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ, Чикина МН, Новикова АМ. Факторы риска сердечно-сосудистых заболеваний у пациентов с болезнью депонирования кристаллов пирофосфата кальция. Научно-практическая ревматология. 2019;57(5):545-552. doi: 10.14412/1995-4484-2019-545-552</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Zhelyabina OV, Chikina MN, Novikova AM. Cardiovascular risk factors in patients with calcium pyrophosphate crystal deposition disease. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(5):545-552 (In Russ.). doi: 10.14412/1995-4484-2019-545-552</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):938-946. doi: 10.1177/2047487315610663</mixed-citation><mixed-citation xml:lang="en">Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):938-946. doi: 10.1177/2047487315610663</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: 10.1038/nature04516</mixed-citation><mixed-citation xml:lang="en">Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: 10.1038/nature04516</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ. How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int. 2009;29(3):229-238. doi: 10.1007/s00296-008-0710-9</mixed-citation><mixed-citation xml:lang="en">Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ. How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int. 2009;29(3):229-238. doi: 10.1007/s00296-008-0710-9</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Mathieu S, Couderc M, Tournadre A, Soubrier M. Cardiovascular profile in osteoarthritis: A meta-analysis of cardiovascular events and risk factors. Joint Bone Spine. 2019;86(6):679-684. doi: 10.1016/j.jbspin.2019.06.013</mixed-citation><mixed-citation xml:lang="en">Mathieu S, Couderc M, Tournadre A, Soubrier M. Cardiovascular profile in osteoarthritis: A meta-analysis of cardiovascular events and risk factors. Joint Bone Spine. 2019;86(6):679-684. doi: 10.1016/j.jbspin.2019.06.013</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandes GS, Valdes AM. Cardiovascular disease and osteoarthritis: Common pathways and patient outcomes. Eur J Clin Invest. 2015;45(4):405-414. doi: 10.1111/eci.12413</mixed-citation><mixed-citation xml:lang="en">Fernandes GS, Valdes AM. Cardiovascular disease and osteoarthritis: Common pathways and patient outcomes. Eur J Clin Invest. 2015;45(4):405-414. doi: 10.1111/eci.12413</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52(24):1949-1956. doi: 10.1016/j.jacc.2008.08.050</mixed-citation><mixed-citation xml:lang="en">Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol. 2008;52(24):1949-1956. doi: 10.1016/j.jacc.2008.08.050</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5(6):819-829. doi: 10.1161/CIRCOUTCOMES.112.967604</mixed-citation><mixed-citation xml:lang="en">Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5(6):819-829. doi: 10.1161/CIRCOUTCOMES.112.967604</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta GK, Agrawal T, DelCore MG, Mohiuddin SM, Agrawal DK. Vitamin D deficiency induces cardiac hypertrophy and inflammation in epicardial adipose tissue in hypercholesterolemic swine. Exp Mol Pathol. 2012;93(1):82-90. doi: 10.1016/j.yexmp.2012.04.006</mixed-citation><mixed-citation xml:lang="en">Gupta GK, Agrawal T, DelCore MG, Mohiuddin SM, Agrawal DK. Vitamin D deficiency induces cardiac hypertrophy and inflammation in epicardial adipose tissue in hypercholesterolemic swine. Exp Mol Pathol. 2012;93(1):82-90. doi: 10.1016/j.yexmp.2012.04.006</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-511. doi: 10.1161/CIRCULATIONAHA.107.706127</mixed-citation><mixed-citation xml:lang="en">Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503-511. doi: 10.1161/CIRCULATIONAHA.107.706127</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Pandit A, Mookadam F, Boddu S, Aryal Pandit A, Tandar A, Chaliki H, et al. Vitamin D levels and left ventricular diastolic function. Open Heart. 2014;1(1):e000011. doi: 10.1136/openhrt-2013-000011</mixed-citation><mixed-citation xml:lang="en">Pandit A, Mookadam F, Boddu S, Aryal Pandit A, Tandar A, Chaliki H, et al. Vitamin D levels and left ventricular diastolic function. Open Heart. 2014;1(1):e000011. doi: 10.1136/openhrt-2013-000011</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gandhi S, Myers RB. Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev. 2013;18(4):465-473. doi: 10.1007/s10741-012-9336-9</mixed-citation><mixed-citation xml:lang="en">Gandhi S, Myers RB. Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev. 2013;18(4):465-473. doi: 10.1007/s10741-012-9336-9</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Niemczyk S. Serum osteoprotegerin is an independent marker of left ventricular hypertrophy, systolic and diastolic dysfunction of the left ventricle and the presence of pericardial fluid in chronic kidney disease patients. Nutrients. 2022;14(14):2893. doi: 10.3390/nu14142893</mixed-citation><mixed-citation xml:lang="en">Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Niemczyk S. Serum osteoprotegerin is an independent marker of left ventricular hypertrophy, systolic and diastolic dysfunction of the left ventricle and the presence of pericardial fluid in chronic kidney disease patients. Nutrients. 2022;14(14):2893. doi: 10.3390/nu14142893</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Georgiopoulos G, Tsioufis C, Kalos T, Magkas N, Roussos D, Chrysohoou C, et al. Serum uric acid is independently associated with diastolic dysfunction in apparently healthy subjects with essential hypertension. Curr Vasc Pharmacol. 2019;17(1): 99-106. doi: 10.2174/1570161116666171226124959</mixed-citation><mixed-citation xml:lang="en">Georgiopoulos G, Tsioufis C, Kalos T, Magkas N, Roussos D, Chrysohoou C, et al. Serum uric acid is independently associated with diastolic dysfunction in apparently healthy subjects with essential hypertension. Curr Vasc Pharmacol. 2019;17(1): 99-106. doi: 10.2174/1570161116666171226124959</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
